MKTXS

Boutique global consultancy producing customized, integrated, & evidence-based strategies for life science companies to optimize product value & patient access

[MKTXS @MKTXS_LLC]

After 2.5 years, MKTXS is excited to share that our team is headed to Vienna for ISPOR EU! Our team is looking forward to insightful, in-person discussions with other attendees, presenting research, opportunities to network, and learn about trending topics within the industry

[MKTXS @MKTXS_LLC]

We r hiring for Evidence Generation and Market Access positions! Do visit us @www_healthecon career fair: https://t.co/78JisMNvsr

[MKTXS @MKTXS_LLC]

Optimal brand defense strategies for combating generic entry – stop by our poster PSY89 @6:45PM to learn more! https://t.co/RT9pOsniCa

[MKTXS @MKTXS_LLC]

What payment models do US Payers see as viable 4 #gene therapies?Visit poster PSY99 @6:45PM 2 learn more! #ispordc https://t.co/4jaPONJhCA

[MKTXS @MKTXS_LLC]

Real-world data simulations provide insights on #biosimilars' #BudgetImpact in US! Stop by PMS22 @645PM #isporDC https://t.co/nvpyRzKiiN

[MKTXS @MKTXS_LLC]

Real-world data simulation provide insights on biosimilars' budget impact 2 US payers! Stop by PMS22 @645PM #isporDC https://t.co/sVPU0gE2HF

[MKTXS @MKTXS_LLC]

#ITC of newer #treatments in #Relapse #Refractory #MultipleMyeloma. Visit PCN25 @1:00 PM to learn more! #ispordc https://t.co/MXFiahkdl4

[MKTXS @MKTXS_LLC]

What's missing in the literature of #inflammatory #myopathies - Visit poster PHS127 @1:00 PM to learn more! #ispordc https://t.co/PpG9RCVfcm

[MKTXS @MKTXS_LLC]

See hw #PCSK9 inhibitors differentiate themselves frm generic #statins.Visit PCV101 @1:00 PM to learn more! #ispordc https://t.co/vuWk0HZFrM

[MKTXS @MKTXS_LLC]

2016 marks 10 yrs fr us!Meet ur team at TT2 at #ISPORDC to learn the latest on #genetherapies #biosimilars & #PCSK9

[MKTXS @MKTXS_LLC]

We are excited to seeing you all at ISPOR ! We will be at table 2 at the consortium level. Do stop by, we would love to say hello! #ispordc

[MKTXS @MKTXS_LLC]

Biosimilars - friend or foe? Our expert opinion on evidence generation considerations in this evolving landscape at https://t.co/skw03SKVCl

[Smeet Gala @GalaSmeet]

Are we blaming #treatments for #deaths more than we should? Check out our @MKTXS_LLC new #CML publication - https://t.co/24bmn05CP7

[Johnson & Johnson Innovation @JNJInnovation]

#JLABSSD landed on @SanDiegoMag’s list of 21 cool things in San Diego! #GoSanDiego https://t.co/segYFRgr68 @ErinKnowsSD

[NICE @NICEComms]

New guidance to help support the independence & mental wellbeing of older people is published today https://t.co/aYGW9ewWLs

[NEJM @NEJM]

Don't miss new page on pain management, addiction, and end-of-life care. https://t.co/BH9vQ5kNhJ

[AstraZenecaUS @AstraZenecaUS]

1st treatment now available for certain patients w/ metastatic #NSCLC #lungcancer https://t.co/eKdlxmaoSj

[MKTXS @MKTXS_LLC]

#Oncology #data @ your fingertips. Learn how OncoLitBank can aid your research at poster PRM51@ 12.45PM #ISPORMilan https://t.co/RKrUw36RxV